Genetics of diabetic retinopathy

References

• Horikawa Y, Iwasaki N, Hara M, Furuta H, Hinokio Y, Cockburn BN, Lindner T, Yamagata K, Ogata M, Tomonaga O, Kuroki H, Kasahara T, Iwamoto Y, Bell GI. Mutation in hepatocyte nuclear factor-1 beta gene (TCF2) associated with MODY. Nat Genet. 1997;17(4):384–385.
   PubMed Web of Science ®Google Scholar
• Yamagata K, Oda N, Kaisaki PJ, Menzel S, Furuta H, Vaxillaire M, Southam L, Cox RD, Lathrop GM, Boriraj VV, Chen X, Cox NJ, Oda Y, Yano H, Le Beau MM, Yamada S, Nishigori H, Takeda J, Fajans SS, Hattersley AT, Iwasaki N, Hansen T, Pedersen O, Polonsky KS, Bell GI et al. Muta- tions in the hepatocyte nuclear factor-1alpha gene in maturity-onset diabetes of the young (MODY3). Nature. 1996;384(6608):455–458.
   PubMed Web of Science ®Google Scholar
• Alcolado JC, Thomas AW. Maternally inherited diabetes mellitus: the role of mitochondrial DNA defects. Diabet Med. 1995;12(2):102–108. Review.
   Google Scholar
• Baynes KC, Whitehead J, Krook A, O’Rahilly S. Molecu- lar mechanisms of inherited insulin resistance. Q J Med. 1997;90(9):557–562. Review.
   Google Scholar
• Hanis CL, Boerwinkle E, Chakraborty R, Ellsworth DL, Concannon P, Stirling B, Morrison VA, Wapelhorst B, Spielman RS, Gogolin-Ewens KJ, Shepard JM, Williams SR, Risch N, Hinds D, Iwasaki N, Ogata M, Omori Y, Petzold C, Rietzch H, Schroder HE, Schulze J, Cox NJ, Menzel S, Boriraj VV, Chen X et al. A genome-wide search for human non-insulin-dependent (type 2) diabetes genes reveals a major susceptibility locus on chromosome 2. Nat Genet. 1996;13(2):161–166.
   Google Scholar
• Todd JA, Farrall M. Panning for gold: genome-wide scanning for linkage in type 1 diabetes. Hum Mol Genet. 1996;5(Spec No):1443–1448. Review.
   Google Scholar
• Seaquist ER, Goetz FC, Rich S, Barbosa J. Familial clus- tering of diabetic kidney disease. Evidence for genetic susceptibility to diabetic nephropathy. N Engl J Med. 1989;320(18):1161–1615.
   PubMed Web of Science ®Google Scholar
• Borch-Johnsen K, Norgaard K, Hommel E, Mathiesen ER, Jensen JS, Deckert T, Parving HH. Is diabetic nephropathy an inherited complication? Kidney Int. 1992;41(4): 719–722.
   Google Scholar
• Quinn M, Angelico MC, Warram JH, Krolewski AS. Familial factors determine the development of diabetic nephropathy in patients with IDDM. Diabetologia. 1996; 39(8):940–945.
   PubMedGoogle Scholar
• The Diabetes Control and Complications Trial Research Group. Clustering of long-term complications in families with diabetes in the diabetes control and complications trial. Diabetes. 1997;46(11):1829–1839.
   Google Scholar
• Alcolado J. Genetics of diabetic complications. Lancet. 1998;24(351):230–231.
   Google Scholar
• Akagi Y, Kador PF, Kuwabara T, Kinoshita JH. Aldose reductase localization in human retinal mural cells. Invest Ophthalmol Vis Sci. 1983;24(11):1516–1519.
   Google Scholar
• Hohman TC, Nishimura C, Robison WG Jr. Aldose reduc- tase and polyol in cultured pericytes of human retinal capillaries. Exp Eye Res. 1989;48(1):55–60.
   Google Scholar
• Greene DA, Lattimer SA, Sima AAF. Sorbitol, phospho- inositides and sodium-potassium ATPase in the pathogene- sis of diabetic complications. N Engl J Med. 1987;316:599–606.
   PubMed Web of Science ®Google Scholar
• Williamson JR, Chang K, Frangos M, Hasan KS, Ido Y, Kawamura T et al. Hyperglycemic pseudohypoxia and diabetic complications. Diabetes. 1993;42:801–813.
   PubMed Web of Science ®Google Scholar
• Ishii H, Jirousek MR, Koya D, Takagi C, Xia P, Clermont A. Amelioration of vascular dysfunctions in diabetic rats by an oral PKC b inhibitor. Science. 1996;272:728–731.
   PubMed Web of Science ®Google Scholar
• Larkins RG, Dunlop ME. The link between hyper-glycemia and diabetic nephropathy. Diabetologia. 1992;35:499–504.
   PubMed Web of Science ®Google Scholar
• Kinoshita JH. Mechanisms initiating cataract formation: Protor lecture. Invest Ophthalmol. 1974;13:713–714.
   PubMedGoogle Scholar
• Dvornik D, Simard-Duquesne N, Krami M, Sestard K, Gabbay KH, Kinoshita JH, Varma SD, Merola LO. Polyol accumulation in galactosemic and diabetic rats: control by an aldose reductase inhibitor. Science. 1973; 182:1146–1148.
   PubMed Web of Science ®Google Scholar
• Willars GB, Townsend J, Tomlinson DR, Compton AM, Churchill RD. Studies on peripheral nerve and lens in long- term experimental diabetes: effects of the aldose reductase inhibitor Statil. Metabolism. 1988;37:442–449.
   Google Scholar
• Mizisin AP, Powell HC. Schwann cell injury is attenuated by aldose reductase inhibition in galactose intoxication. J Neuropathol Exp Neurol. 1993;52:78–86.
   PubMed Web of Science ®Google Scholar
• Robison WG Jr, Kador PF, Kinoshita JH. Retinal capil- laries: basement membrane thickening by galactosemia prevented with aldose reductase inhibitor. Science. 1983;221:1177–1179.
   Google Scholar
• Frank RN, Keirn RJ, Kennedy A, Frank KW. Galactose- induced retinal capillary basement membrane thickening: prevention by sorbinil. Invest Ophthalmol Visual Sci. 1983;24:1519–1524.
   PubMed Web of Science ®Google Scholar
• Kador PF, Akagi Y, Terubayashi H, Wyman M, Kínoshita JH. Prevention of pericyte ghost formation in retinal capil- laries of galactose fed dogs by aldose reductase inhibitors. Arch Ophthalmol. 1988;106:1099–1102.
   PubMedGoogle Scholar
• Robinson WG Jr, Natata M, Laver N, Hohman TC, Kinoshita JH. Diabetic like retinopathy in rats prevented with an aldose reductase inhibitor. Invest Ophthalmol Visual Sci. 1989;30:2285–2292.
   Google Scholar
• Kador PF, Akagi Y, Takahashi Y, Ikebe H, Wyman M, Kinoshita JH. Prevention of retinal vessel changes associ- ated with diabetic retinopathy in galactose fed dogs by aldose reductase inhibitors. Arch Ophthalmol. 1990;108:1301–1309.
   PubMed Web of Science ®Google Scholar
• Li W, Khatami M, Rockey JH. The effect of glucose and an aldose reductase inhibitor on the sorbitol content and collagen synthesis of bovine retinal capillary pericytes in culture. Exp Eye Res. 1985;40:439–444.
   Google Scholar
• Krontiris TG. Minisatellites and human disease. Science. 1995;269:1682–1683.
   Google Scholar
• Ko BC-B, Lam KS-L, Wat NM-S, Chung SS-M. An (AC)n dinucleotide repeat polymorphic marker at the 5¢ end of the aldose reductase gene is associated with early-onset diabetic retinopathy in NIDDM patients. Diabetes. 1995;44:727–732.
   PubMed Web of Science ®Google Scholar
• Olmos P, Futers S, Acosta AM, Siegel S, Maiz A et al. (AC)23 [Z-2] polymorphism of the aldose reductase gene and fast progression of retinopathy in Chilean type 2 diabetics. Diabetes Res Clin Pract. 2000;47:169–176.
   PubMed Web of Science ®Google Scholar
• Kao YL, Donaghue K, Chan A, Knight J, Silink M. A novel polymorphism in the aldose reductase gene promoter region is strongly associated with diabetic retinopathy in adolescents with type 1 diabetes. Diabetes. 1999;48(6): 1338–1340.
   Google Scholar
• Henry DN, Del Monte M, Greene DA, Killen PD. Altered aldose reductase gene regulation in cultured human retinal pigment epithelial cells. J Clin Invest. 1993;92(2):617– 623.
   Google Scholar
• Heessom AK, Hibberd ML, Millward A, De-maine AG. Polymorphism in the 5¢ end of the aldose reductase gene is strongly associated with the development of diabetic nephropathy in type I diabetes. Diabetes. 1997;46:287–291.
   Google Scholar
• Kao YL, Donaghue K, Chan A, Knight J, Silink M. An aldose reductase intragenic polymorphism associated with diabetic retinopathy. Diabetes Res Clin Pract. 1999;46(2): 155–160.
   Google Scholar
• Barbosa J, Bach FH, Rich SS. Genetic heterogeneity of diabetes and HLA. Clin Genet. 1982;21(1):25–32.
   Google Scholar
• Agardh D, Gaur LK, Agardh E, Landin-Olsson M, Agardh CD, Lernmark A. HLA-DQB1*0201/0302 is associated with severe retinopathy in patients with IDDM. Diabetolo- gia. 1996;39(11):1313–1317.
   Google Scholar
• Naji A, Silvers WK, Barker CF. Autoimmunity and type I (insulin-dependent) diabetes mellitus. Transplantation. 1983;36(4):355–361.
   Google Scholar
• Barbosa J, Saner B. Do genetic factors play a role in the pathogenesis of diabetic microangiopathy? Diabetologia. 1984;27(5):487–492. Review.
   Google Scholar
• Bodansky HJ, Wolf E, Cudworth AG, Dean BM, Nineham LJ, Bottazzo GF, Matthews JA, Kurtz AB, Kohner EM. Genetic and immunologic factors in microvascular disease in type I insulin-dependent diabetes. Diabetes. 1982;31(1): 70–74.
   Google Scholar
• Schernthaner G, Ludwig H, Mayr WR. Immunoglobulin G- insulin antibodies and immune region-associated alloanti- gens in insulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1979;48(3):403–407.
   Google Scholar
• Ballerman BJ, Zeidel ML, Gunning ME, Brenner BM. Vasoactive peptides and the kidney. In: Brenner BM, Rector FC. Eds. The Kidney. 4th ed. Philadelphia Saunders, 1991;510–583.
   Google Scholar
• Merimee TJ. Diabetic retinopathy. A synthesis of perspec- tives. N Engl J Med. 1990;322(14):978–983. Review.
   Google Scholar
• Rabensteiner D, Abrahamian H, Irsigler K, Hermann KM, Kiener HP, Mayer G, Kaider A, Prager R. ACE gene poly- morphism and proliferative retinopathy in type 1 diabetes: results of a case-control study. Diabetes Care. 1999;22(9): 1530–1535.
   Google Scholar
• Fujisawa T, Ikegami H, Kawaguchi Y, Hamada Y, Ueda H, Shintani M, Fukuda M, Ogihara T. Meta-analysis of asso- ciation of insertion/deletion polymorphism of angiotensin I-converting enzyme gene with diabetic nephropathy and retinopathy. Diabetologia. 1998;41(1):47–53.
   Google Scholar
• Lieberman J, Sastre A. Serum angiotensin-converting enzyme: elevations in diabetes mellitus. Ann Intern Med. 1980;93(6):825–826.
   PubMed Web of Science ®Google Scholar
• Migdalis IN, Iliopoulou V, Kalogeropoulou K, Koutoulidis K, Samartzis M. Elevated serum levels of angiotensin-converting enzyme in patients with diabetic retinopathy. South Med J. 1990;83(4):425–427.
   Google Scholar
• Feman SS, Mericle RA, Reed GW, May JM, Workman RJ. Serum angiotensin converting enzyme in diabetic patients. Am J Med Sci. 1993;305(5):280–284.
   Google Scholar
• Tiret L, Rigat B, Visvikis S, Breda C, Corvol P, Cambien F, Soubrier F. Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I- converting enzyme (ACE) gene controls plasma ACE levels. Am J Hum Genet. 1992;51(1):197–205.
   PubMed Web of Science ®Google Scholar
• Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest. 1990;86(4):1343–1346.
   PubMed Web of Science ®Google Scholar
• Danser AH, Derkx FH, Admiraal PJ, Deinum J, de Jong PT, Schalekamp MA. Angiotensin levels in the eye. Invest Oph- thalmol Vis Sci. 1994;35(3):1008–1018.
   PubMed Web of Science ®Google Scholar
• Chaturvedi N, Sjolie AK, Stephenson JM, Abrahamian H, Keipes M, Castellarin A, Rogulja-Pepeonik Z, Fuller JH. Effect of lisinopril on progression of retinopathy in nor- motensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet. 1998; 351(9095):28–31.
   PubMed Web of Science ®Google Scholar
• Larsen M, Hommel E, Parving HH, Lund-Andersen H. Protective effect of captopril on the blood-retina barrier in normotensive insulin-dependent diabetic patients with nephropathy and background retinopathy. Graefes Arch Clin Exp Ophthalmol. 1990;228(6):505–509.
   Google Scholar
• Jackson WE, Holmes DL, Garg SK, Harris S, Chase HP. Angiotensin-converting enzyme inhibitor therapy and diabetic retinopathy. Ann Ophthalmol. 1992;24(3):99–103.
   Google Scholar
• Santoro SA, Zutter MM. The alpha 2 beta 1 integrin: a collagen receptor on platelets and other cells. Thromb Haemost. 1995;74(3):813–821. Review.
   Google Scholar
• Sixma JJ, van Zanten GH, Huizinga EG, van der Plas RM, Verkley M, Wu YP, Gros P, de Groot PG. Platelet adhesion to collagen: an update. Thromb Haemost. 1997;78(1): 434–438. Review.
   Google Scholar
• Winocour PD. Platelet abnormalities in diabetes mellitus. Diabetes. 1992;41(Suppl 2):26–31. Review.
   Google Scholar
• Mustard JF, Packham MA. Platelets and diabetes mellitus. N Engl J Med. 1984;311(23):1518–1520.
   Google Scholar
• Rasi V, Ikkala E, Hekali R, Myllyla G. Factors affecting plasma beta-thromboglobulin in diabetes mellitus. Med Biol. 1980;58(5):269–272.
   Google Scholar
• Dallinger KJ, Jennings PE, Toop MJ, Gyde OH, Barnett AH. Platelet aggregation and coagulation factors in insulin dependent diabetics with and without microangiopathy. Diabet Med. 1987;4(1):44–48.
   Google Scholar
• Kamata T, Puzon W, Takada Y. Identification of putative ligand binding sites within I domain of integrin alpha 2 beta 1 (VLA-2, CD49b/CD29). J Biol Chem. 1994;269(13): 9659–9663.
   Google Scholar
• Kritzik M, Savage B, Nugent DJ, Santoso S, Ruggeri ZM, Kunicki TJ. Nucleotide polymorphisms in the alpha2 gene define multiple alleles that are associated with differences in platelet alpha2 beta1 density. Blood. 1998;92(7):2382– 2388.
   Google Scholar
• Kunicki TJ, Kritzik M, Annis DS, Nugent DJ. Hereditary variation in platelet integrin alpha 2 beta 1 density is asso- ciated with two silent polymorphisms in the alpha 2 gene coding sequence. Blood. 1997;89(6):1939–1943.
   PubMed Web of Science ®Google Scholar
• Carlsson LE, Santoso S, Spitzer C, Kessler C, Greinacher A. The alpha2 gene coding sequence T807/A873 of the platelet collagen receptor integrin alpha2beta1 might be a genetic risk factor for the development of stroke in younger patients. Blood. 1999;93(11):3583–3586.
   PubMed Web of Science ®Google Scholar
• Moshfegh K, Wuillemin WA, Redondo M, Lammle B, Beer JH, Liechti-Gallati S, Meyer BJ. Association of two silent polymorphisms of platelet glycoprotein Ia/IIa receptor with risk of myocardial infarction: a case-control study. Lancet. 1999;353(9150):351–354.
   Google Scholar
• Yumiko Matsubara, Mitsuru Murata, Taro Maruyama, Makoto Handa, Norihiko Yamagata, Gentaro Watanabe, Takao Saruta, and Yasuo Ikeda. Association between dia- betic retinopathy and genetic variations in alpha2beta1 inte- grin, a platelet receptor for collagen. Blood. 2000;95:1560–1564.
   PubMed Web of Science ®Google Scholar
• The TIMAD Study Group. Ticlopidine treatment reduces the progression of nonproliferative diabetic retinopathy. Arch Ophthalmol. 1990;108(11):1577–1583.
   Google Scholar
• Giustina A, Perini P, Desenzani P, Bossoni S, Ianniello P, Milani M, Davi G, Romanelli G. Long-term treatment with the dual antithromboxane agent picotamide decreases microalbuminuria in normotensive type 2 diabetic patients. Diabetes. 1998;47(3):423–430.
   Google Scholar
• Tikkanen I, Fyhrquist F. Nitric oxide in hypertension and renal diseases. Ann Med. 1995;27(3):353–357. Review.
   Google Scholar
• Gryglewski RJ, Chlopicki S, Swies J, Niezabitowski P. Prostacyclin, nitric oxide, and atherosclerosis. Ann N Y Acad Sci. 1995;17(748):194–206.
   Google Scholar
• Williams SB, Cusco JA, Roddy MA, Johnstone MT, Creager MA. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J Am Coll Cardiol. 1996;27(3):567–574.
   PubMed Web of Science ®Google Scholar
• Cooke JP, Dzau VJ. Nitric oxide synthase: role in the genesis of vascular disease. Annu Rev Med. 1997;48:489–509.Review.
   Google Scholar
• Larson DM, Carson MP, Haudenschild CC. Junctional transfer of small molecules in cultured bovine brain microvascular endothelial cells and pericytes. Microvasc Res. 1987;34(2):184–199.
   Google Scholar
• Mandarino LJ. Current hypotheses for the biochemical basis of diabetic retinopathy. Diabetes Care. 1992;15 (12):1892–1901. Review.
   Google Scholar
• Roufail E, Stringer M, Rees S. Nitric oxide synthase immunoreactivity and NADPH diaphorase staining are co- localised in neurons closely associated with the vasculature in rat and human retina. Brain Res. 1995;684(1):36–46.
   Google Scholar
• Ye X, Laties AM, Stone RA. Peptidergic innervation of the retinal vasculature and optic nerve head. Invest. Ophthal- mol. 1990;31:1731–1737.
   PubMed Web of Science ®Google Scholar
• Chakravarthy U, Hayes RG, Stitt AW, Douglas A. Increased ET1 expression in ocular tissues of diabetic animals. Invest. Ophthalmol. 1997;38:2144–2151.
   Google Scholar
• Tesfamariam B, Brown ML, Deykin D, Cohen RA. Ele- vated glucose promotes generation of endothelium-derived vasoconstrictor proteinoids in rabbit aorta. J Clin Invest. 1990;85:929–993.
   PubMedGoogle Scholar
• Stehouwer CDA, Lambert J, Donker AJM, van Hinsberg VWM. Endothelial dysfunction and pathogenesis of dia- betic angiopathy. Cardiovasc Res. 1997;34:55–68.
   PubMed Web of Science ®Google Scholar
• Feener EP, King GL. Vascular dysfunction in diabetes mel- litus. Lancet. 1997;350:9–13.
   Web of Science ®Google Scholar
• Cai H, Wang X, Colagiuri S, Wilcken DE. A common Glu298 Æ Asp (894G Æ T) mutation at exon 7 of the endothelial nitric oxide synthase gene and vascular com- plications in type 2 diabetes. Diabetes Care. 1998;21(12): 2195–2196.
   Google Scholar
• Walston J, Silver K, Bogardus C, Knowler WC, Celi FS, Austin S, Manning B, Strosberg AD, Stern MP, Raben N et al. Time of onset of non-insulin-dependent diabetes mel- litus and genetic variation in the beta 3-adrenergic-receptor gene. N Engl J Med. 1995;333(6):343–347.
   PubMed Web of Science ®Google Scholar
• Widen E, Lehto M, Kanninen T, Walston J, Shuldiner AR, Groop LC. Association of a polymorphism in the beta 3- adrenergic-receptor gene with features of the insulin resis- tance syndrome in Finns. N Engl J Med. 1995;333(6): 348–351.
   Google Scholar
• Clement K, Vaisse C, Manning BS, Basdevant A, Guy- Grand B, Ruiz J, Silver KD, Shuldiner AR, Froguel P, Strosberg AD. Genetic variation in the beta 3-adrenergic receptor and an increased capacity to gain weight in patients with morbid obesity. N Engl J Med. 1995;333(6):352–354.
   PubMed Web of Science ®Google Scholar
• Yoshida T, Sakane N, Umekawa T, Sakai M, Takahashi T, Kondo M. Mutation of beta 3-adrenergic-receptor gene and response to treatment of obesity. Lancet. 1995;346:1433– 1434.
   Google Scholar
• Fujisawa T, Ikegami H, Yamato E, Takekawa K, Nakagawa Y, Hamada Y, Oga T, Ueda H, Shintani M, Fukuda M, Ogihara T. Association of Trp64Arg mutation of the beta3- adrenergic-receptor with NIDDM and body weight gain. Diabetologia. 1996;39(3):349–352.
   Google Scholar
• Yoshioka K, Yoshida T, Sakane N, Umekawa T, Takahashi T, Sakai Y, Kondo M. Association of Trp64Arg mutation of the beta 3-adrenergic receptor gene with NIDDM, current and maximal body mass index. Diabetologia. 1996;39(11): 1410–1411.
   Google Scholar
• Sakane N, Yoshida T, Yoshioka K, Nakamura Y, Umekawa T, Kogure A, Takakura Y, Kondo M. Beta 3-adrenoreceptor gene polymorphism: a newly identified risk factor for proliferative retinopathy in NIDDM patients. Diabetes. 1997;46(10):1633–1636.
   Google Scholar
• Berlan M, Galitzky J, Bousquet-Melou A, Lafontan M, Montastruc JL. Beta-3 adrenoceptor-mediated increase in cutaneous blood flow in the dog. J Pharmacol Exp Ther. 1994;268(3):1444–1451.
   Google Scholar
• Atef N, Lafontan M, Double A, Helary C, Ktorza A, Penicaud L. A specific beta 3-adrenoceptor agonist induces increased pancreatic islet blood flow and insulin secretion in rats. Eur J Pharmacol. 1996;298(3):287–92.
   Google Scholar
• Wiman B, Hamsten A. The fibrinolytic enzyme system and its role in the etiology of thromboembolic disease. Semin Thromb Hemost. 1990;16(3):207–216. Review.
   Google Scholar
• Auwerx J, Bouillon R, Collen D, Geboers J. Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus. Arteriosclerosis. 1988; 8(1):68–72.
   Google Scholar
• Juhan-Vague I, Roul C, Alessi MC, Ardissone JP, Heim M, Vague P. Increased plasminogen activator inhibitor activity in non insulin dependent diabetic patients–relationship with plasma insulin. Thromb Haemost. 1989;61(3):370– 373.
   Google Scholar
• Nagi DK, Mohamed Ali V, Jain SK, Walji S, Yudkin JS. Plasminogen activator inhibitor (PAI-1) activity is elevated in Asian and Caucasian subjects with non-insulin- dependent (type 2) diabetes but not in those with impaired glucose tolerance (IGT) or non-Asians. Diabet Med. 1996;13(1):59–64.
   Google Scholar
• Gough SC, Rice PJ, McCormack L, Chapman C, Grant PJ. The relationship between plasminogen activator inhibitor-1 and insulin resistance in newly diagnosed type 2 diabetes mellitus. Diabet Med. 1993;10(7):638–642.
   Google Scholar
• Haitas B, Barnes AJ, Cederholm-Williams SA, Moore J, Shogry ME, Turner RC. Abnormal endothelial release of fibrinolytic activity and fibronectin in diabetic microan- giopathy. Diabetologia. 1984;27(5):493–496.
   Google Scholar
• Ostermann H, Tschope D, Greber W, Meyer-Rusenberg HW, van de Loo J. Enhancement of spontaneous fibrinolytic activity in diabetic retinopathy. Thromb Haemost. 1992; 68(4):400–403.
   Google Scholar
• Cagliero E, Roth T, Roy S, Maiello M, Lorenzi M. Expres- sion of genes related to the extracellular matrix in human endothelial cells. Differential modulation by elevated glu- cose concentrations, phorbol esters, and cAMP. J Biol Chem. 1991;266(22):14244–14250.
   Google Scholar
• Knowler WC, Bennett PH, Hamman RF, Miller M. Dia- betes incidence and prevalence in Pima Indians: a 19-fold greater incidence than in Rochester, Minnesota. Am J Epidemiol. 1978;108(6):497–505.
   Google Scholar
• Knowler WC, Bennett PH, Bottazzo GF, Doniach D. Islet cell antibodies and diabetes mellitus in Pima Indians. Diabetologia. 1979;17(3):161–164.
   Google Scholar
• Nagi DK, McCormack LJ, Mohamed-Ali V, Yudkin JS, Knowler WC, Grant PJ. Diabetic retinopathy, promoter (4G/5G) polymorphism of PAI-1 gene, and PAI-1 activity in Pima Indians with type 2 diabetes. Diabetes Care. 1997;20(8):1304–1309.
   Google Scholar
• Eriksson P, Kallin B, van’t Hooft FM, Bavenholm P, Hamsten A. Allele-specific increase in basal transcription of the plasminogen-activator inhibitor 1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA. 1995;92(6):1851–1855.
   PubMed Web of Science ®Google Scholar
• Schneiderman J, Sawdey MS, Keeton MR, Bordin GM, Bernstein EF, Dilley RB, Loskutoff DJ. Increased type 1 plasminogen activator inhibitor gene expression in athero-sclerotic human arteries. Proc Natl Acad Sci USA. 1992;89(15):6998–7002.
   Google Scholar
• Juhan-Vague I, Alessi MC. Plasminogen activator inhibitor 1 and atherothrombosis. Thromb Haemost. 1993;70 (1):138–143. Review.
   Google Scholar
• Munjal ID, McLean NV, Grant MB, Blake DA. Differences in the synthesis of secreted proteins in human retinal endothelial cells of diabetic and nondiabetic origin. Curr Eye Res. 1994;13(4):303–310.
   PubMed Web of Science ®Google Scholar
• Grant MB, Guay C. Plasminogen activator production by human retinal endothelial cells of nondiabetic and diabetic origin. Invest Ophthalmol Vis Sci. 1991;32(1):53–64.
   PubMed Web of Science ®Google Scholar
• Sanghera DK, Aston CE, Saha N, Kamboh MI. DNA poly- morphisms in two paraoxonase genes (PON1 and PON2) are associated with the risk of coronary heart disease. Am J Hum Genet. 1998;62(1):36–44.
   PubMed Web of Science ®Google Scholar
• Hegele RA, Connelly PW, Scherer SW, Hanley AJ, Harris SB, Tsui LC, Zinman B. Paraoxonase-2 G148 variant in an aboriginal Canadian girl with non-insulin-dependent diabetes. Lancet. 1997;350(9080):785.
   Google Scholar
• Hegele RA, Connelly PW, Scherer SW, Hanley AJ, Harris SB, Tsui LC, Zinman B. Paraoxonase-2 gene (PON2) G148 variant associated with elevated fasting plasma glucose in noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1997;82(10):3373–3377.
   Web of Science ®Google Scholar
• Odawara M, Tachi Y, Yamashita K. Paraoxonase polymor- phism (Gln192-Arg) is associated with coronary heart disease in Japanese noninsulin-dependent diabetes mellitus. J Clin Endocrinol Metab. 1997;82(7):2257– 2260.
   Google Scholar
• Garin MC, James RW, Dussoix P, Blanche H, Passa P, Froguel P, Ruiz J. Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J Clin Invest. 1997;99(1):62–66.
   PubMed Web of Science ®Google Scholar
• Serrato M, Marian AJ. A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. J Clin Invest. 1995; 96(6):3005–3008.
   Google Scholar
• Kao YL, Donaghue K, Chan A, Knight J, Silink M. A variant of paraoxonase (PON1) gene is associated with diabetic retinopathy in IDDM. J Clin Endocrinol Metab. 1998;83(7):2589–2592.
   PubMed Web of Science ®Google Scholar
• Takata K, Hirano H, Kasahara M. Transport of glucose across the blood-tissue barriers. Int Rev Cytol. 1997;172:1–53.
   PubMed Web of Science ®Google Scholar
• Harik SI, Kalaria RN, Whitney PM et al. Glucose trans- porters are abundant in cells with occluding junctions at the blood-eye barriers. Proc Natl Acad Sci USA. 1990;87:4261–4264.
   PubMed Web of Science ®Google Scholar
• Mantych GJ, Hageman GS, Devaskar SU. Characterization of glucose transporter isoforms in the adult and developing human eye. Endocrinology. 1993;133:600–607.
   PubMed Web of Science ®Google Scholar
• Kumagai AK, Glasgow BJ, Pardridge WM. GLUT1 glucose transporter expression in the human diabetic and nondia- betic eye. Invest Ophthalmol Vis Sci. 1994;35:2887–2889.
   Google Scholar
• King GL, Kunisaki M, Nishio Y, Inoguchi T, Shiba T, Xia P. Biochemical and molecular mechanisms in the devel- opment of diabetic vascular complications. Diabetes. 1996;45:S105–S108.
   PubMed Web of Science ®Google Scholar
• Lorenzi M. Glucose toxicity in the vascular complications of diabetes: the cellular perspective. Diabetes Metab Rev. 1992;8:85–103.
   PubMedGoogle Scholar
• Kumagai AK. Glucose transport in brain and retina: impli- cations in the management and complications of diabetes. Diabetes Metab Res Rev. 1999;15(4):261–273. Review.
   Google Scholar
• Kumagai AK, Vinores SA, Pardridge WM. Pathological up- regulation of inner blood-retinal barrier GLUT1 glucose transporter expression in diabetes mellitus. Brain Res. 1996;706:313–317.
   Google Scholar
• Roy S. Distribution and expression of GLUT1 in the retina of the galactose-fed rat. [ARVO Abstract]. Invest Ophthal- mol Vis Sci. 1996;37:S970.
   Google Scholar
• Poulsom R, Prockop DJ, Boot-Handford RP. Effects of long-term diabetes and galactosaemia upon lens and retinal mRNA levels in the rat. Exp Eye Res. 1990;51:27–32.
   Google Scholar